Description
Ipamorelin’s selective GHSR agonism produces clean pulsatile GH release without the cortisol, prolactin, or hunger side effects that made earlier GHRPs unsuitable for women. At 10mg, this vial supports a full 12-week protocol at standard doses, or a 16-week protocol at conservative female dosing, making it ideal for women who prefer to purchase a complete cycle supply without interruption.
Extended ipamorelin protocols in women typically show progressive IGF-1 elevation over 8–12 weeks, with associated benefits in lean mass preservation, collagen density, and bone mineral content. Sleep quality improvements are often reported in the first 2–3 weeks and tend to be the earliest indicator of protocol response. The 10mg format is also the logical choice for women stacking Ipamorelin with CJC-1295 No DAC from separate vials, allowing independent dose titration.
Female-calibrated dosing: 100–200mcg subcutaneously at bedtime, 5 days/week. Reconstitute with 5mL bacteriostatic water for a standard 200mcg/mL concentration. Run 12-week cycles with a 4-week break, or continue in ongoing rotation at lower doses under clinical guidance.
Storage: Store lyophilized powder below -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.






Reviews
There are no reviews yet.